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Abstract
Dysferlin is critical for repair of muscle membranes after damage. Mutations in dysferlin lead to a progressive muscular
dystrophy. Recent studies suggest additional roles for dysferlin. We set out to study dysferlin’s protein-protein interactions
to obtain comprehensive knowledge of dysferlin functionalities in a myogenic context. We developed a robust and
reproducible method to isolate dysferlin protein complexes from cells and tissue. We analyzed the composition of these
complexes in cultured myoblasts, myotubes and skeletal muscle tissue by mass spectrometry and subsequently inferred
potential protein functions through bioinformatics analyses. Our data confirm previously reported interactions and support
a function for dysferlin as a vesicle trafficking protein. In addition novel potential functionalities were uncovered, including
phagocytosis and focal adhesion. Our data reveal that the dysferlin protein complex has a dynamic composition as a
function of myogenic differentiation. We provide additional experimental evidence and show dysferlin localization to, and
interaction with the focal adhesion protein vinculin at the sarcolemma. Finally, our studies reveal evidence for cross-talk
between dysferlin and its protein family member myoferlin. Together our analyses show that dysferlin is not only a
membrane repair protein but also important for muscle membrane maintenance and integrity.
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Introduction
Dysferlin (DYSF, MIM*603009) is a 230 kDa large transmem-
brane protein highly expressed in striated muscle and to a lesser
extent in other tissues, including monocytes, syncytiotrophoblast,
endothelium, brain, pancreas, and kidney.[1] Dysferlin is found
intracellularly on vesicles and at the plasma membrane. Upon
laser-inflicted membrane damage dysferlin rapidly accumulates at
the site of the lesion in a calcium dependent manner, and
participates in patch-fusion repair. In the absence of dysferlin the
membrane tear is not adequately repaired and the myofiber will
undergo necrosis.[2]
Mutations in the dysferlin gene cause a spectrum of adult-onset
progressive muscular dystrophies including Limb Girdle Muscular
Dystrophy type 2B (LGMD2B, MIM#253601), Myoshi Myopa-
thy (MM, MIM#254130), and Distal Anterior Compartment
Myopathy (DACM, MIM#606768), commonly referred to as
dysferlinopathies.[3–5] There is no clear genotype-phenotype
correlation and the ,150 described mutations cover the complete
open reading frame. (www.dmd.nl/dysf) It is therefore unclear
how defects in the DYSF gene cause muscular dystrophy. It has
been suggested that the skeletal muscle membrane is continuously
subject to mechanical wear and tear, and that the dysferlin
deficiency phenotype results from inefficient membrane repair in
response to continued membrane damage.[6] Dysferlin knockout
mice develop a phenotype similar to the dysferlinopathies.[2]
Dysferlin contains seven C2 domains, two DysF domains and a
C-terminal transmembrane domain. C2 domains are calcium
sensitive phospholipid binding domains, as was also shown for the
first C2 domain (C2A) of dysferlin [7], and are thought to be
important for regulating dysferlin trafficking. These domains have
also been shown to interact with proteins.[8] The function of the
DysF domain remains unclear.[9] Dysferlin (also known as ferlin1-
like 1, FER1L1) belongs to the family of ferlin-like proteins that
includes otoferlin (FER1L2, MIM *603681), myoferlin (FER1L3,
MIM *604603), FER1L4, FER1L5 and FER1L6. The family is
named after ferlin, a Caenorhabditis elegans gene that when mutated
causes infertility [10] and muscle dysfunction [11]. Ferlin is
essential for the fusion of vesicles with the cell membrane.[10]
Mutations in otoferlin cause an autosomal recessive form of
congenital deafness (DFNB9, MIM #601071).[12] Otoferlin is
expressed in hair cells in the inner ear [13], and participates in the
trafficking of synaptosomal vesicles.[14] Myoferlin is like dysferlin
strongly expressed in muscle.[15] It has been suggested that
myoferlin might be able to replace dysferlin as a potential strategy
for therapy of dysferlinopathies.[15,16] The exact function of
myoferlin remains unclear. FER1L4, FER1L5 and FER1L6
proteins have not yet been characterized.
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it is less clear how the protein is regulated. Likely it requires binding
partners that aid in vesicle nucleation, localization, targeting and
recycling. To date only few of such cofactors have been identified,
yet they yielded important insight into dysferlin function.
MG53 (TRIM72, MIM *613288) is a redox sensor that
participates in vesicle nucleation.[17] It can interact with
dysferlin.[18] Together with the dysferlin interacting protein
caveolin 3 it is involved in the trafficking of dysferlin to and from
the sarcolemma.[18–20] In addition, annexins A1 and A2 can
bind dysferlin in a calcium-dependent manner.[21] These proteins
are membrane fusogens that participate in lysosome exocyto-
sis.[22] They are thought to aid in dysferlin vesicle targeting. The
cysteine protease Calpain 3 (CAPN3, MIM *114240) co-
immunoprecipitates with dysferlin in skeletal muscle.[23,24] It is
hypothesized to play a role in cytoskeleton remodeling, [24,25]
and is predicted to remodel cytoskeletal structures to allow for
patch fusion repair.[24,26,27] Finally, AHNAK (MIM *103390) is
found on enlargosomes which have been implicated in membrane
enlargement and repair.[28–30] AHNAK interacts with dysferlin
in skeletal muscle, an interaction that is regulated by calpain 3
activity.[24] These protein interactions have thus yielded some
information on dysferlin function in membrane repair.
Recent data however, suggests that dysferlin is more than a
membrane repair protein. It has been shown to be involved in
cytokine [31] and chemokine [32] secretion and associates with
developing t-tubules.[33] In fertilized sea urchin embryo’s
dysferlin participates in extracellular ATP signaling.[34] More-
over, a defect in membrane repair cannot fully explain the
patient’s phenotype, which has been reported to include renal [35]
and cardiac failure [36]. In addition, dysferlin is considered to be a
very dynamic protein, which is found in the cytosol in myoblasts
and regenerating myofibers, but shows a more prominent
membranous localization in mature skeletal muscle tissue.[31] It
was shown that dysferlin trafficking and endocytosis depend on its
direct interaction with caveolin 3.[19,20,37]
We hypothesized that a comprehensive overview of dysferlin
function can be inferred from large-scale proteomics analysis of
dysferlin protein complexes. Dissecting complex protein structures
requires highly specific affinity binders. We have previously
described heavy chain antibody fragments (HCAb) that specifically
recognize dysferlin in mice and humans.[23] These HCAb make
for exceptional tools to dissect the dysferlin protein complex due to
their strong performance in immunoprecipitation (IP) experi-
ments. By immunoprecipitation of endogenous dysferlin from
human skeletal muscle followed by mass-spectrometry and western
blotting we could previously identify calpain 3 and AHNAK to
interact with dysferlin.[8,23]
In this study we compared dysferlin protein complexes from
proliferating myoblasts, differentiated myotubes and mature
skeletal muscle tissue. We show that 1) we can efficiently and
reproducibly immunoprecipitate dysferlin protein complexes from
these sources, 2) bioinformatics analyses of mass spectrometry
identified proteins confirm a role for dysferlin as a vesicle protein,
and 3) such analyses reveal new layers of dysferlin function which
we substantiated by further exploring interactions with myoferlin,
and focal adhesion components.
Results
Robust and reproducible isolation of dysferlin protein
complexes
As dysferlin expression is reported to increase with myogenic
differentiation we hypothesized that the composition of its protein
complex might also change during this process. Therefore we
aimed to isolate dysferlin protein complexes from different stages
of myogenic differentiation. We used the IM2 cell model [38] as a
source for dysferlin protein complexes to establish the optimal
immunoprecipitation conditions. This cell line can be grown
indefinitely under permissive conditions, and switched to myo-
genic differentiation by serum deprivation. The IM2 cell model
performs more consistently than the C2C12 cell line in terms of
myogenic capacity and differentiates within a shorter time-span.
We first established by western blotting that IM2 cells express
dysferlin (Figure 1). Dysferlin expression increases with differen-
tiation, in line with previous data from C2C12 myoblast cells [39].
Calpain 3, an established partner in the dysferlin protein complex
is also expressed in these cells (Figure 1).
We previously reported two dysferlin specific llama heavy chain
antibody fragments (HCAb) that can specifically immunoprecip-
itate dysferlin from human skeletal muscle.[23] We adapted the
immunoprecipitation method for cultured cells by testing different
buffer conditions (Figure 2). We used the two reported dysferlin
HCAb fragments, F4 and H7 [23], and compared their
performance to a non-specific HCAb (3A), selected against
amyloid-b [40] and which does not recognize dysferlin. We
selected three different lysis buffers for our experiments. The first
buffer is of low ionic strength and contains 0.2% Triton. Triton is
a comparatively mild non-denaturing non-ionic detergent. The
second buffer is of high ionic strength containing SDS and TEA
and has a strong solubilizing capacity. At the used concentration
(0.1%) SDS acts as a partially denaturing detergent that is efficient
at breaking low-afinity protein-protein interactions. The third
buffer contains CHAPS (0.15%) and is of intermediate strength.
CHAPS is a nondenaturing zwitterionic detergent that is useful for
solubilizing membrane proteins. The CHAPS buffer has been used
previously to precipitate dysferlin protein complexes from muscle
tissue with HCAb [23] and with conventional antibodies [37].
Both anti-dysferlin HCAb can precipitate protein complexes in
a mild buffer with low Triton concentration (Figure 2A) whereas
Figure 1. Dysferlin is upregulated during myogenic differen-
tiation in IM2 cells. IM2 cells were differentiated and harvested at day
0, 1, 3 and 5. Protein lysates were probed on western blot for Dysferlin
(upper panel) and Calpain 3 (lower panel).
doi:10.1371/journal.pone.0013854.g001
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other proteins. The zwitter-ionic buffer (CHAPS) results in a
reduction of IP efficiency, consistent with the increased stringency
of the buffer. Again, the non-specific HCAb does not immuno-
precipitate detectable protein amounts. Finally we lysed the cells in
SDS buffer (0.1%). The SDS is predicted to disfavor transient
interactions and should therefore result in a decreased IP of
dysferlin complexes. As predicted, only a limited amount of
proteins coimmunoprecipitate with H7 in SDS buffer. F4
however, immunoprecipitates an increased number of proteins.
A concomitant western blot for dysferlin and its interaction
partner calpain 3 confirmed the Coomassie blue stained gels
(Figures 2B (myoblasts) and 2C (myotubes)). From this we
conclude that the HCAb can be used in different buffer conditions,
and that H7 is the HCAb of choice for qualitative IP experiments,
while F4 can be used for confirmation experiments. Moreover, the
Triton buffer yields the highest level of protein complexes and is
therefore preferred as lysis buffer. Because it is more difficult to
homogenize tissue than cultured cells, we decided to use CHAPS
buffer for skeletal muscle tissue as we have done previously [23].
Figure 2. Reproducible dysferlin immunoprecipitation under different conditions. IM2 myoblasts and myotubes were lysed in three
different buffers and subjected to a HCAb Dysferlin immuno precipitation protocol. F4 and H7 are specific for Dysferlin while 3A is a non-specfic
control HCAb. A) Coomassie stained gel of immunoprecipitation fractions from myoblasts. B) western blot for Dysferlin and Calpain 3 corresponding
to the gel in A. C) A similar western blot on myotubes IP fractions (corresponding gel not shown).
doi:10.1371/journal.pone.0013854.g002
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skeletal muscle tissue
We continued with preparing lysates for IM2 myoblasts, IM2
myotubes at 5 days post-differentiation, when spontaneous
contraction was observed, and human skeletal muscle tissue. After
cell lysis in Triton buffer or tissue homogenization in CHAPS
buffer, dysferlin protein complexes were immunoprecipitated from
these lysates using HCAb H7, separated on SDS-PAGE gels and
stained with Coomassie-blue for further mass spectrometry
analysis (Figure 3a). We monitored the IP procedure with western
blot (Figure S1). The IP was confirmed by western blot with a
conventional antibody specific for dysferlin. (Figures S1 and 3b)
With western blotting we could confirm six of the described
interactions (TUBA[41] (Figure S1) CAPN3[23], AHNAK[8]
(both in Figure S2), PARVB[42], DHPR[43], ANXA2[21] (data
not shown), summarized in Figure 3c. Mass spectrometry analysis
confirmed the presence of one additional reported dysferlin
interaction partner (MG53[18] Table S1), but also resulted in
the identification of many new putative binding partners (complete
lists in table S1). Skeletal muscle cells contain a large amount of
sarcomeric proteins, and components of the dystrophin glycopro-
tein complex (DGC). We did not observe the core DGC
components in the IP fractions, and the amount of sarcomeric
proteins is low, consistent with the fact that the HCAb specifically
Figure 3. Immunoprecipitation of dysferlin from different myogenic sources is highly reproducible. A) Coomassie blue stained gel of IP
fractions from IM2 myoblasts, myotubes and skeletal muscle tissue. IP samples of two dysferlin specific HCAb (F4 and H7) yield highly similar staining
patterns, contrary to a non-specific HCAb (3A). B) a concomitant western blot for dysferlin confirms the IP. C) All protein bands stained in A), lanes H7,
were excised, in-gel trypsin digested and analyzed by mass spectrometry. Many described interaction partners of dysferlin were identified by western
blot (Figure S2) and thus confirmed.
doi:10.1371/journal.pone.0013854.g003
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IP method efficiently and reproducibly enriches for dysferlin
protein complexes.
In our IP data set for myoblasts we identified 521 proteins
annotated in online databases, 344 proteins in myotubes and 229
proteins in skeletal muscle tissue (full lists in supplemental tables S1
and S2). 115 proteins are shared by all datasets (Figure 4). These
proteins we therefore consider a core-set of most likely dysferlin
interacting proteins, or representative of functionalities of dysferlin
that do not change during differentiation. As mentioned before,
the tissue IP was performed under more stringent conditions.
Interestingly, 85% of the proteins identified in the tissue IP were
also identified in the cultured cells. This underlines the
reproducibility of the IP experiment, and indicates a relatively
low number of proteins that nonspecifically co-immunoprecipitate
with dysferlin. An unexpected finding was that there are no
proteins shared by IP from tissue and myotube alone. This might
be explained by the more stringent conditions used for tissue
homogenization.
Potential interaction between dysferlin and myoferlin
We were surprised to consistently identify the dysferlin homolog
myoferlin to co-immunoprecipitate with dysferlin (Mascot protein
score of 300, 12 unique peptides in myoblast IP sample). We do
not think this occurs due to cross reactivity of our antibodies.
Myoferlin shares 68% amino acid sequence similarity with
dysferlin.[15] However, the dysferlin HCAb were previously
shown not to cross-react with recombinant myoferlin.[23]
Moreover, the dysferlin HCAb failed to immunoprecipitate
proteins from dysferlin negative myoblasts and myotubes, as
judged from Coomassie stained gels and western blots for dysferlin
and myoferlin (not shown). Finally, when we used western blotting
to confirm the presence of full-length myoferlin in the H7 and F4
IP fractions (Figure 5), we observed that it is absent in the control
HCAb 3A fractions. Highest levels of myoferlin are detected in the
myoblast IP fractions. We therefore think that dysferlin and
myoferlin can interact. We further verified this interaction using
U2OS cells which express myoferlin but not dysferlin (Figure 5b).
We performed IP experiments on non-transfected U2OS cells, and
U2OS cells transiently transfected with recombinant dysferlin and
analyzed IP fractions on western blot. As expected, F4 and H7
cannot immunoprecipitate myoferlin from wild-type U2OS cells
(Figure 5b). We could only detect myoferlin, but not dysferlin, in
the non-bound fractions, showing that U2OS cells only express
myoferlin. This is also additional support that the HCAb are
specific for dysferlin and cannot directly bind to myoferlin.
However, myoferlin is co-immunoprecipitated from U2OS cells
expressing recombinant dysferlin (Figure 5b, F4). Thus, F4 can
immunoprecipitate myoferlin, albeit weakly, only when dysferlin is
co-expressed. According to previous studies myoferlin is strongly
expressed in myoblasts and prominently in mature muscle
myonuclear membranes, and to a lesser extent at the sarcolem-
ma.[15] Dysferlin is mostly observed at the sarcolemma. This
indicates that only a small fraction of both proteins co-occur in
muscle tissue, consistent with the observation that only a fraction
of myoferlin co-immunoprecipitates with dysferlin. All together
this indicates that myoferlin and dysferlin can be part of the same
protein complex, and opens the possibility of their co-existence in
a single protein complex in muscle.
Bioinformatics analysis of all identified complex partners
We continued with the three data sets of putative dysferlin
interacting proteins and performed bioinformatics analyses to
characterize the dysferlin protein complex. We first analyzed the
datasets with the STRING interaction database (http://string-db.
org/). STRING contains information of known annotated protein-
protein interactions. 14 dysferlin protein protein interactions are
recorded in STRING for human and mouse, of which 6 are direct
interactions described in PubMed references (CAV3, CAPN3,
AHNAK, PARVB, ANXA1, ANXA2). The others are interactions
inferred from co-occurrence in MedLine abstracts and protein
databases. Protein-protein interactions described in recently
published studies, such as TUBA [41], are not yet annotated, and
therefore not included in STRING. The remaining 8 predicted
dysferlin interactions in STRING are not supported by experimen-
tal evidence and include DGC partners. These interactions are not
identified in our data sets, and we consider them unlikely given the
existingliteratureondysferlin.Thus,STRINGdoesnotcontainany
information on the dysferlin protein complex partners, and
therefore we consider the majority of interactions identified with
our IP experiments as novel dysferlin interactions.
Literature analysis of the dysferlin protein complex
We then verified whether there was any prior support in the
biomedical literature for the identified interactions of dysferlin by
calculating and comparing the textual overlap in MedLine abstracts
for dysferlin and other proteins (Figure S3). We used the concept
profile text-mining technique.[44] In this method all concepts (e.g.
proteins, diseases, chemicals, GO terms) that are associated with a
given protein identifier in MedLine abstracts are assembled into a
concept profile. The amount of overlapping concepts between two
proteins is a measure of relatedness; it records both explicit (co-
mentioning of two proteins in the same abstract) and implicit (both
proteins co-mentioned with a third concept) relationships. We
ranked all putative interaction partners based on their match scores
and subsequently analyzed, through Area under the ROC Curve
(AuC) analysis, whether the identified interaction partners of
dysferlin were among the top ranked proteins. An AuC of 0.5
would imply that the identified proteins are ranked randomly over
the whole range of proteins, while an AuC of 1 would imply that all
top-ranked proteins co-immunoprecipiate with dysferlin. We
obtained an AuC of ,0.8 (Figure S3A), indicating that the proteins
indentifiedin the IP experimentsarerelated to dysferlin inMedLine
abstracts, and may share similar functions and/or pathways. In
Table 1A we list the top 9 proteins that share strongest conceptual
overlapwith dysferlin.Thisincludestwoofthedescribedinteraction
Figure 4. Venn diagram showing the overlap of dysferlin
interaction partners in myoblast, myotubes and skeletal
muscle tissue. All Coomassie stained bands from the H7 IP shown
in Figure 3A were excised, in-gel digested and analyzed by mass
spectrometry. 115 proteins are consistently identified in all three
protein sources.
doi:10.1371/journal.pone.0013854.g004
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partners. To gain a better idea of which type of concepts associate
with the dysferlin protein complex we clustered the identified
proteins and subsequently annotated with concepts. Representative
concepts for the observed clusters are shown in Table 1B (full table
in S3), and include vesicle related concepts such as Kinesin Activity
and Membrane Protein Traffic, consistent with the vesicular
localization of dysferlin. However, also many novel associations
are uncovered, such as Translation Initiation, Actin Cortical Patch,
and Chaperonin Activity. These concepts may refer to novel
dysferlin functionalities.
Given that dysferlin expression is not restricted to skeletal
muscle, we next evaluated co-expression of the dysferlin protein
complex partners over multiple tissues, using the database Gene
Atlas. We obtained an AuC of ,0.7 (Figure S3B), where an AuC
of 0.5 would mean a random level co-expression and an AuC of
1.0 would mean complete co-expression. This result suggests that
we do not mainly identify muscle specific proteins.
Gene Ontology analysis of the dysferlin protein complex
Gene Ontology (GO) category analysis is commonly used for
bioinformatics analysis of large datasets. We used the DAVID web
tool to analyze GO category enrichment by performing a cluster
analysis (Table 2, full table in S4). Protein lists were uploaded in
DAVID and compared to a random background data set(shown) or
a random set of muscle genes (not shown) with comparable results.
The output is a ranked set of GO term clusters that are significantly
overrepresented in the IP data sets (Table 2). Many of the highest
ranked clusters relate to vesicle trafficking (in bold). Examples of
such proteins are Clathrin and Rab GTPases. This corroborates the
reported function of dysferlin as a vesicular protein. In addition to
vesicle trafficking, several other clusters are significantly represent-
ed, which may point to potential novel roles for dysferlin function.
Many identified proteins relate to ATP binding and purine
synthesis. This finding is interesting as a recent study showed that
dysferlin is involved in extracellular ATP and ADP signaling. One
of the indentified target proteins, found in all data sets, is ATP
synthase (ATP5b).
A large number of mitochondrial proteins is indentified in the
dysferlin protein complex. 18 proteins are observed in the core-set
of 115 proteins. This includes proteins that localize to the outer
and inner mitochondrial membrane, indicating that large parts of
mitochondrial membranes co-purify with dysferlin. Intriguingly,
the alternative first exon of dysferlin [45] encodes a putative
Figure 5. Myoferlin and dysferlin may be present in the same protein complex. A) Dysferlin IP fractions were stained in western blot with a
myoferlin specific antibody, to verify that full-length dysferlin is co-immunoprecipitated with dysferlin, and not with the control HCAb 3A. B) U2OS
cells, which express endogenous myoferlin but not dysferlin, were transfected with dysferlin cDNA or empty vector (mock), and both untransfected
(wild-type) and transfected cells were lysed and subjected to an IP experiment with F4 and H7. IP and non-bound fractions were analyzed on western
blot for dysferlin (lower panel) and myoferlin (upper panel). F4 and H7 can only immunoprecipitate dysferlin from dysferlin transfected cells (lower
panel), consistent with the absence of endogenous dysferlin expression. Myoferlin is not immunoprecipitated from wild-type cells, though it can be
detected in the non-bound fractions. However, myoferlin is immunoprecipitated by F4 from dysferlin expressing U2OS cells (band marked by
asterisk).
doi:10.1371/journal.pone.0013854.g005
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that dysferlin is targeted to mitochondria in myoblasts.
Finally, among the top ranked clusters in all three data-sets,
including the core set of 115 proteins, are clusters that relate to
protein translation and folding. A possible explanation for this is
that ER-residing dysferlin is immunoprecipitated from the cells.
KEGG pathway analysis of the dysferlin protein complex
We proceeded with a KEGG pathway analysis, which gives a
better visualization how the identified dysferlin protein complex
partners relate to each other (table S5). Interestingly, the strongest
vesicle-related KEGG pathway in all three data sets is endocytosis,
rather than exocytosis. This is consistent with previous studies
which suggested that dysferlin undergoes rapid endocytosis in the
absence of caveolin 3 on the cell membrane.[19] Additionally,
dysferlin negative cells show an upregulation of endocytotic
proteins [46], again suggesting a role for dysferlin in endocytosis.
Most proteins that are found upregulated by Nagaraju et al [46]
are coimmunoprecipitated with dysferlin, and include Mannose-6
phosphate receptor (CIMPR, or IGF2R), adaptin (AP2), clathrin-a
(CLTA) and the GTPase RAC2 (Table S1). Interestingly, this
KEGG pathway analysis also revealed several immunological
pathways, such as Fc gamma R-mediated phagocytosis. As
dysferlin is also expressed in monocytes [47–49], this indicates
that common pathways may exist between muscle and monocytes.
Multiple pathways are ranked higher than Endocytosis, but do
not relate directly to vesicles. The top-ranked pathway is
Metabolic Enzymes, which includes most of the mitochondrial
proteins identified in the IPs. This indicates a role for dysferlin in
energy metabolism. However, due to the high content of metabolic
enzymes in muscle, some aspecific interactions cannot be
excluded. Of interest is the presence of creatine kinase M and B.
Serum levels of creatine kinase are exceptionally high in
dysferlinopathy patients, reaching 100 fold above normal.[50]
Table 1. Concept analysis of the identified dysferlin protein complex partners.
A Myoblasts Myotubes Tissue
1 MYOF MYOF MYOF
2 VCL TRIM72 VCL
3 EIF3B LDB3 EIF3B
4 CAPZB VCL DCTN1
5 DCTN1 EIF3B LMNA
6 ANXA2 CAPZB HSP90B1
7 UTRN ACTN2 NEDD4L
8 EIF2S1 TTN HSPA5
9 LMNA ANXA2 STAT1
B Myoblasts Myotubes Tissue
1 kinesin activity Translation Initiation kinesin activity
2 dynein activity protein disulfide isomerase activity dynein activity
3 Myosin ATPase chaperonin activity Translation Initiation
4 membrane protein traffic heat-shock response chaperonin activity
5 Antigen Processing ribonucleoprotein complex location heat-shock response
6 Translation Initiation ubiquitin activity ubiquitin activity
7 transfer RNA Actin myofilament cell-cell adhesion
8 heat-shock response phosphatase citric acid cycle
9 chaperonin activity Keratins
10 ribosomal protein activity pre-replicative complex
11 ribonucleoprotein complex location
12 Growth Cones
13 actin cap
14 actin cortical patch
15 Cytoskeleton
16 Intermediate Filaments
17 ubiquitin activity
18 nucleocytoplasmic transport
19 phosphatase
20 phosphatase
21 cyclin-dependent protein kinase activity
A) For each data set the proteins were assigned to concept profiles (summary of all concepts such as proteins, diseases and GO terms to associate with a given protein
identifier), and conceptual overlap with dysferlin was calculated. The 9 proteins with strongest conceptual overlap are listed and include described interaction partners
(in bold). B) Identified proteins were first clustered and subsequently annotated with concepts. Representative concepts for the uncovered clusters are shown for each
data set (full table in S3).
doi:10.1371/journal.pone.0013854.t001
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ranked high in all 3 data sets. Focal adhesions and tight junctions
are two structures involved in cell-cell and cell-matrix contacts, in
which the intracellular actin cytoskeleton is linked by transmem-
brane proteins to extracellular proteins. These adhesion sites exist
independently of the DGC, and previous cellular fractionation
experiments have shown that integrins, which are part of focal
adhesions, are restricted to different membrane sections than the
DGC.[51] While we do not identify DGC components in the
dysferlin protein complex, several focal adhesion proteins were
identified in all three sources, including vinculin (VINC), actinin
(ACTN), and talin (TLN). This hints at a role for dysferlin in cell
adhesion.
In all, the three datasets indicate dysferlin function beyond
muscle membrane repair.
Dysferlin can interact with the focal adhesion component
vinculin
To validate our bioinformatics analysis we further investigated
one of the newly identified pathways: Focal Adhesion. Vinculin
has strong conceptual overlap with dysferlin (VCL in Table 1A).
Interestingly, the previously reported dysferlin interactor PARVB
localizes to and regulates focal adhesions.[42] PARVB can directly
interact with ILK and dysferlin, and regulates focal adhesion
turnover.[42,52,53] In the absence of dysferlin, PARVB is no
longer recruited to the sarcolemma.[42] To confirm the existence
of focal adhesion components in the dysferlin protein complex we
verified that both dysferlin HCAbs can co-immunoprecipitate full-
length vinculin (VINC) (Figure 6a). A vinculin doublet, corre-
sponding to two vinculin isoforms [54], is detected consistently in
the dysferlin HCAb IP fractions, but not in controls. Interestingly,
the relative amount of immunoprecipitated vinculin decreases with
differentiation, suggesting that the interaction is dynamic. To
further support the validity of this interaction we performed the
reverse experiment and used conventional antibodies against
vinculin to co-immunoprecipitate dysferlin (Figure 6b). These
antibodies can efficiently co-immunoprecipitate dysferlin from
cultured myotubes, unlike isotype control antibodies, indicating
the validity of their interaction. We performed additional
immunofluorescent analysis of human skeletal muscle cryosections.
As shown in Figure 6c, vinculin is found predominantly at the
sarcolemma in cross-sections, and colocalizes with dysferlin.
Discussion
We have identified a large set of potential dysferlin protein
complex partners in a myogenic context. We showed that many
new complex partners participate in vesicle trafficking, which
corroborates previous data that dysferlin is involved in this process
and suggest that its interaction partners, such as Clathrin, assist in
this function. In addition we identified several potential novel roles
for dysferlin, including cell adhesion, metabolism, mitochondrial
association, and immune cell function.
Table 2. DAVID annotation of clusters in the IP lists.
Myoblasts Myotubes Tissue Core set
1 GO:0006412,translation GO:0043292,contractile fiber GO:0005524,ATP binding GO:0006457,protein folding
2 GO:0005524,ATP binding GO:0043232,intracellular non-
membrane-bounded organelle
GO:0006457,protein folding GO:0005524,ATP binding
3 GO:0043232,intracellular non-
membrane-bounded organelle
GO:0005524,ATP binding GO:0043232,intracellular non-
membrane-bounded organelle
GO:0043232,intracellular non-
membrane-bounded organelle
4 GO:0016023,cytoplasmic
membrane-bounded vesicle
GO:0006412,translation GO:0043623,cellular protein
complex assembly
GO:0016023,cytoplasmic
membrane-bounded vesicle
5 GO:0015031,protein transport GO:0016023,cytoplasmic
membrane-bounded vesicle
GO:0006412,translation GO:0043292,contractile fiber
6 GO:0006457,protein folding GO:0006457,protein folding GO:0007018,microtubule-
based movement
GO:0006986,response to unfolded
protein
7 GO:0006413,translational initiation GO:0006096,glycolysis GO:0016023,cytoplasmic
membrane-bounded vesicle
GO:0042623,ATPase activity, coupled
8 GO:0005739,mitochondrion GO:0015629,actin cytoskeleton GO:0006986,response to unfolded
protein
GO:0007018,microtubule-based
movement
9 GO:0008180,signalosome GO:0005739,mitochondrion GO:0030529,ribonucleoprotein
complex
GO:0031974,membrane-enclosed
lumen
10 GO:0003924,GTPase activity GO:0045333,cellular respiration GO:0015031,protein transport GO:0006412,translation
11 GO:0030036,actin cytoskeleton
organization
GO:0005882,intermediate filament GO:0005882,intermediate filament GO:0030017,sarcomere
12 GO:0006418,tRNA aminoacylation
for protein translation
GO:0000502,proteasome complex GO:0031974,membrane-
enclosed lumen
GO:0000502,proteasome complex
13 GO:0006096,glycolysis GO:0006418,tRNA aminoacylation
for protein translation
GO:0006163,purine nucleotide
metabolic process
GO:0005882,intermediate filament
14 GO:0005882,intermediate filament GO:0006936,muscle contraction GO:0016887,ATPase activity GO:0006418,tRNA aminoacylation for
protein translation
All three datasets were analyzed separately. Protein lists were uploaded in DAVID and analyzed against a random set of genes as background. A p-value was calculated
for all GO terms, and those GO terms that were significantly overrepresented compared to the background set were clustered. Subsequent ranking of clusters is
determined by the combined p-value. For each cluster a representative GO term is shown in the table. Full tables are in S4. The pathways that relate to vesicles are
enhanced in bold.
doi:10.1371/journal.pone.0013854.t002
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13854Figure 6. A potential interaction between dysferlin and vinculin. A) The dysferlin IP samples were analyzed on western blot for vinculin, to
verify that full-length vinculin specifically co-immunoprecipitates with dysferlin, but not with the 3A control HCAb. B) cell lysate of IM2 myotubes
were subjected to immunoprecipitate with antibodies against vinculin and an IgG control (against VSV), and IP and non-bound fractions were
analyzed for dysferlin on western blot. HCAb F4 and 3A were taken along as positive and negative controls, respectively. Dysferlin is strongly
detected in the F4 fraction (upper panel). Weak signal is also seen in the vinculin bound fractions, indicating a weak interaction with dysferlin. A
corresponding western blot for vinculin shows the presence of full-length vinculin in the F4 and vinculin IP fractions (lower panel). C) Human skeletal
muscle cryosections were stained for vinculin (green) and dysferlin (F4, red). In cross-sections (right) both dysferlin and vinculin are detected at the
sarcolemma.
doi:10.1371/journal.pone.0013854.g006
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Figure 2. Such differences in performance are not unique to
HCAb, and it is difficult to predict and establish why this occurs. It
might be that the antibodies compete with interaction partners at
the site of antigen binding, or that the epitope availability is not
uniform. The latter has been described for dysferlin as C2 domains
are calcium sensitive [7], and VHH are known to recognize three
dimensional folds [55].
It must be noted that the IP procedure does not discriminate
between direct and indirect interactions. We aimed to limit the
potential problem of non-specific binders by analyzing two
dysferlin specific HCAb and using different myogenic sources
and buffers with different solubilizing properties. Although it
cannot be excluded that some co-immunoprecipitated proteins are
non-specific binders, the large overlap of immunoprecipiated
proteins in all three sources under different stringency conditions,
and their absence in the control experiments, indicates that most
IP proteins are valid complex partners of dysferlin, whether direct
or indirect. In addition, we tested and confirmed 8 of 9 established
protein-protein interactions of dysferlin, and provided biochemical
evidence for the novel interactions with myoferlin and vinculin.
Finally, an additional indication for the validity of the method is
that no components of the DGC were identified.
Myoferlin was consistently identified in the dysferlin protein
complex. Given the specificity of all antibodies used in this study
we do consider this interaction to be genuine. It is interesting to
speculate that dysferlin could form oligomers with its homologous
family member myoferlin, and how this contributes to protein
function, possibly patch-fusion repair.
115 Proteins were consistently immunoprecipitated from all
three protein sources. These proteins we consider to be the
strongest candidates for dysferlin complex partners, or represent
functionalities of dysferlin that do not change with differentiation.
The proteins that were identified only in a subset of sources can be
explained in three ways: 1) by expression differences (eg. MG53
(TRIM72) is not expressed in myoblasts and therefore only
immunoprecipitated from myotubes, Table S1), 2) as non-specific
binders, or 3) representing a change in dysferlin function during
muscle differentiation.
We often observed in our western blots that the relative
amounts of immunoprecipitated proteins often changes with
differentiation. Examples of such dynamic protein-protein inter-
actions of dysferlin are calpain 3 (Figure 2B, C) myoferlin
(Figure 5A) and vinculin (Figure 6a). This suggests that the
dysferlin protein complex has a dynamic nature as a function of
myogenic differentiation. When we further compared the specific
proteins for each dataset, we noticed that a high number of
mitochondrial proteins was co-immunoprecipitated from myo-
blasts (20%, not shown). This amount decreases with differenti-
ation and is lowest in tissue (12%). In contrast, the relative amount
of metabolic enzymes from the glycolysis pathway is enriched with
differentiation (going from 2% to 4%). This may indicate that the
function of dysferlin changes with differentiation. Unfortunately
our qualitative analysis does not allow for solid quantitative
conclusions due to its dependence on experimental conditions.
Future studies using quantitative proteomic approaches may give a
clearer impression of the relative abundance of the protein
identified in the dysferlin protein complex during certain
processes.
Among the identified mitochondrial proteins is ATP synthase
(ATP5b). ATP synthase is a protein complex enriched in
mitochondria and part of the respiratory chain.[56] In addition
ATP5b is also found at the cell membrane, where it maintains
extracellular ATP and ADP levels, and functions as a membrane
receptor for HDL.[56] It was recently shown that dysferlin is
involved in extracellular ATP and ADP signaling.[34] It is
tempting to speculate that the putative interaction between
Dysferlin and ATP synthase allows for the formation of vesicle
with ATP content to participate in the repair process.
Many of the identified novel dysferlin protein interactions relate
to protein translation and folding. It was recently suggested that
pathogenic mutations in dysferlin result in improper folding of the
protein and therefore in dysfunction and degradation.[57]
Moreover, it has been shown that the ER can function as an
intracellular storage compartment of recombinant dysferlin [58],
which is in line with elongated translation/folding time. Therefore
we feel that the identified interactions between dysferlin and
several ER proteins are not an artifact but reflect the amount of
effort that the muscle cells invest into proper folding of the
230 kDa protein.
It has been shown that most of recombinant dysferlin localizes
to the ER, and that ER-residing recombinant dysferlin can be
targeted to two distinct routes of degradation: ERAD and stress-
induced autophagy.[58] The latter process depends on phosphor-
ylation of EIF2 and the autophagy gene MAP1/LC3.[58]
Interestingly, both proteins were identified to co-immunoprecip-
itate with endogenous dysferlin (Table S1), suggesting that a
similar autophagy route also exists for endogenous dysferlin in
vivo. In addition, it was shown that recombinant dysferlin interacts
with the chaperones VCP and SEC61 [58] as part of the ERAD
pathway. Both VCP and SEC61 co-immunoprecipitate with
endogenous dysferlin.
Based on the high ranking of the Focal Adhesion KEGG
pathway in all data sets we focused our attention on this pathway.
Mutations in the focal adhesion components ITGA7[59], and
VINC[54] result in a muscle pathology. Interestingly, integrins
and FAK have been shown to be essential for myogenic
differentiation and localize at the site of fusion.[60–62] Dysferlin
shows a similar localization in differentiated myotubes.[33] This
indicates that dysferlin might be involved in regulation of cell-cell
contacts. Interestingly, a recent screen identified integrins (the
transmembrane components of focal adhesions) to be essential for
endocytosis in HeLa cells.[63] This is in line with our finding that
dysferlin co-immunoprecipitates endocytic proteins.
Dysferlin was previously described to be involved in membrane
repair. For membrane repair to occur, the cell needs to patch the
damaged membrane, and remodel the local cytoskeleton [26]. It
has been shown that at the site of damage, cytoskeletal proteins
talin and vimentin are proteolytically processed by calpains.[26]
Moreover, at this site integrins and actin rapidly accumulate [26],
suggesting cytoskeletal remodeling of the cortical cytoskeleton, and
the adhesion sites. It is tempting to speculate that dysferlin is
involved in both processes. Through its membrane association it
can target vesicular membrane stores, and through its interaction
with focal adhesion components it can coordinate cytoskeletal
remodeling. Previous work showed that dysferlin recruits PARVB
to the sarcolemma.[42] PARVB can directly interact with integrin
linked kinase, and is important for stabilizing focal adhe-
sions.[52,53] In the absence of dysferlin PARVB does not localize
to the sarcolemma, but the functional consequence of this is
unknown.[42] Calpain 3 is also in complex with dysferlin. Through
its proteolytic activity it can modulate the direct interaction
between dysferlin and the giant protein AHNAK.[24] Thus,
dysferlin might act as a sensor to coordinate the remodeling of
structuralproteinsinadditionto aiding patch-fusionof membranes.
In conclusion we observed that dysferlin participates in diverse
processes in a spatiotemporal dependent manner, that together
ensure proper maintenance of skeletal muscle membrane integrity.
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Cell culture
Mouse IM2 myoblast were maintained under permissive
conditions at 33uC and 10% CO2 in DMEM (61965, GIBCO)
supplemented with L-Glutamine, 1% Pen/Strep (100IU/100UG/
ML, Gibco-BRL), 20% FCS, IFN-c, and Chick embryo extract.
For differentiation cells were grownt to 70% confluency, washed
with PBS and grown in DMEM (61965) supplemented with 10%
HS, L-Glutamine, and Pen/Strep.
Antibodies
The following antibodies were used in this study: MaCAPN3
(NCL-12A2 Novocastra) at 1;500 for western blot. MaVSV (P5D4
gift from Dr. J. Fransen, Nijmegen, The Netherlands) at 1;5,000
for IF. MaDYSF (Hamlet, Novocastra) at 1;300 for western blot
and IHC. MaMYOF (gift from Dr. R. Bashir), GaMousealexa488
(Molecular Probes, Eugene, OR, USA), GaRabbitalexa594
(Molecular Probes) at 1;1,000 and 1;2,000, respectively. GaR-
abbitIRDye800 and GaMouseIRDye680 (Westburg) were used at
1;5,000 for western blotting.
Immunoprecipitation
The following lysis buffers were used: Triton buffer (50 mM
TrisHCl, pH 7.5, 150 mM NaCl, 0.2% Triton X100, 1x protease
inhibitor cocktail (Roche)), CHAPS buffer (50 mM Tris-HCl
pH 7.5, 150 mM NaCl, 0.15% CHAPS and 1x protease inhibitor
cocktail), or SDS buffer (20 mM triethanolamine 0,14 M NaCl,
0,1% DOC, 0,1% SDS, 0,1% triton X100, protease inhibitor
cocktail). Cultured cells were prepared freshly by washing in PBS
and lysed by scraping on ice in cold lysis buffer. Proteins Snap-
frozen human skeletal muscle tissue was homogenized in CHAPS
buffer. All homogenates were spun down at maximum speed, 4uC,
20 min. The pellet was discarded as debris. The supernatant
containing the solubilized proteins was cleared with protein A
Sepahrose CL-4B (Amersham). The Sepharose was first pre-
equilibrated by a 3x wash in lysis buffer and added to the
homogenates for 1 h, at 4uC tumbling. Sepharose was removed
and antibody added (50 mg HCAb, or 10 mg conventional
antibody) for O/N incubation at 4uC tumbling. Thereafter pre-
equilibrated Sepharose was added and incubated for 2 h, 4uC,
tumbling). Homogenates were spun down at 500 g and superna-
tant stored as non-bound fraction. The Sepharose was washed 5x
(.5 min tumbling at 4uC). Finally, all fluid was removed and
protein eluted by boiling in sample buffer. This was analyzed as
the IP or bound fraction.
Western blot
Cell lysates were prepared in Llaemli sample buffer and loaded
onto SDS-PAGE gels. Proteins were separated and blotted onto
PVDF membranes. Blots were washed, blocked in 4% mPBS for
30 min, and incubated with primary antibody diluted in blocking
buffer for 2 h at RT. Subsequent washes in PBS-tween were
followed with 1 h incubation with secondary antibody in the dark.
Blots were washed and scanned with an odyssey scanner (Licor,
Lincoln, Nebraska, USA).
Immunostaining
For immunohistochemical examinations, muscle cryosections of
6 mm thickness were fixed in 3.7% formaldehyde in phosphate-
buffer saline (PBS) containing 0.1% Triton X-100 for 30 min,
following by pre-incubation with 4% skimmed milk (Marvel) in
PBS at room temperature for 2 h. The sections were incubated
with primary antibody o/n at 4 ˚C, and subsequently by incubation
of fluorescein-labeled secondary antibody for 1 h min at RT. The
sections were washed with PBS, dehydrated with (subsequently)
70, 90, 100% ethanol and mounted in a DAPI (50 ng/ml)/
Vectashield mounting medium (Burlingame). Final preparations
were analyzed with a Leica Aristoplan fluorescence microscope
and images were obtained using a Cytovision (Applied imaging)
digital system.
In-gel tryptic digestion
IP fractions were separated on SDS-PAGE gels, and proteins
were visualized with Coomassie (SimplyBlue, Invitrogen). Gel
lanes were sliced into 25–30 bands, cut into small pieces and
washed with 25 mM NH4HCO3 followed by two rounds of
dehydration with 100% acetonitrile for 10 min. For reduction and
alkylation, gel particles were first incubated with 10 mM
dithiothreitol for 30 minutes at 56 uC. Following dehydration
with acetonitrile, gel plugs were subsequently incubated in 55 mM
iodoacetamide for 20 minutes at room temperature. After two
rounds of washing with 25 mM NH4HCO3 and dehydration with
100% acetonitrile, the gel particles were completely dried in a
centrifugal vacuum concentrator (Eppendorf, Hamburg, Ger-
many). Dried gel particles were re-swollen for 15 min. on ice by
addition of 15 ml of a trypsin solution (12.5 ng/mli n2 5 m M
NH4HCO3, Sequencing grade modified trypsin, Promega,
Madison, WI). Following this, 20 ml of 25 mM NH4HCO3 was
added and samples were kept on ice for an additional 30 min.
Tryptic digestion was subsequently performed overnight at 37 uC.
Following tryptic digestion, the overlaying digestion-solution was
collected. Two additional rounds of extraction with 20 ml 0.1%
TFA were used to extract peptides from the gel plugs and all
extracts were pooled.
Nano LC ESI MS/MS
Nanoflow LC was performed on an Ultimate LC system
(Dionex, Sunnyvale, CA). A volume of 10 mL of sample was
injected onto a C18 PepMapTM 0.3 mm65 mm trapping column
(Dionex) and washed with 100% A (2% acetonitrile in 0.1%
formic acid in MQ water, v/v) at 20 mL/min for 15 min.
Following valve switching, peptides were separated on a C18
PepMap 75 mm6150 mm column (Dionex) at a constant flow of
200 nL/min. The peptide elution gradient was from 10 to 60% B
(95% acetonitrile in 0.1% formic acid in MQ water v/v) over
50 min. The nanoflow LC system was coupled to an HCTultra
IonTrap (Bruker Daltonics, Bremen, Germany) using a nano-
electrospray ionisation source. The spray voltage was set at 1.2 kV
and the temperature of the heated capillary was set to 165 uC.
Eluting peptides were analyzed using the data dependent MS/MS
mode over a 300–1500 m/z range. The five most abundant ions
in an MS spectrum were selected for MS/MS analysis by collision-
induced dissociation using helium as the collision gas.
Mass spectrometry data analysis
Peak lists were generated using DataAnalysis 4.0 software
(Bruker Daltonics) and exported as Mascot Generic (MGF) files.
These files were searched against the mouse (myoblast and
myotube samples) or the human (muscle sample) IPI database
using the Mascot (version 2.2.1) search algorithm (Matrix Science,
London, UK) and data from 1 lane were merged using Mascot
Deamon. An MS tolerance of 0.6 Da (with # 13C=1) and a MS/
MS tolerance of 0.5 Da was used. Trypsin was designated as the
enzyme and up to one missed cleavage site was allowed.
Carbamidomethylcysteine was selected as a fixed modification
and oxidation of methionine as a variable modification. Only
significant protein hits with at least one unique peptide with a
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to concepts. Proteins for which insufficient data was available to
create a concept were discarded. To make sure that the remaining
‘‘single peptide’’ hits did not strongly influence the data analysis we
performed the bioinformatics analyses of the myoblast data with a
more stringent data set requiring a minimum of 2 unique peptides,
and obtained comparable results (not shown).
Text-mining analysis
To calculate the similarity of the contexts in which proteins
appear in literature, we summarize the context of each protein in a
concept profile. This profile contains all concepts that have a
direct relation with a protein as found in Medline abstracts. The
concepts in a profile include, in addition to proteins, all other
concepts described in the Unified Medical Language System
(UMLS), such as diseases, symptoms, tissues, biological processes
and many other types of concepts. For a detailed description of
concept profiles we refer to Jelier et al.[44] The similarity score
between two concept profiles is taken as the inner product of the
concept profile vectors.
Co-expression analysis
Microarray co-expression data (human GNF1H chip) were
downloaded from Gene Atlas (http://biogps.gnf.org/downloads/).
First the log was taken from the MAS5.0 normalized expression
values for each tissue (78 in total). Then a Pearson correlation was
calculated over these values.
Bioinformatics
IPI numbers retrieved from Mascot were mapped to GENE
identifiers using the NCBI mapping. GENE lists were analyzed
using the webtool DAVID (http://david.abcc.ncifcrf.gov/), using
functional annotation clustering. The following settings were used:
GOTERM_BP_FAT, GOTERM_CC_FAT, GOTERM_MF_
FAT, COG_ONTOLOGY, SP_PIR_KEYWORDS, UP_SEQ_
FEATURE. KEGG Pathways were analyzed separately. The
analyses were done with a random gene set as background, and
subsequently with a muscle specific (obtained from C2C12 micro-
array experiments) gene set, for confirmation.
A Functional Annotation Clustering was performed, and rank
determined by the software, based on an enrichment score
calculated from the separate p-values for each GO-term associated
with a cluster. Whole output tables are included in the supplement.
Representative GO terms for each cluster are included in
summarizing Table 1.
Separately, the gene lists were analyzed with the web tool
KEGG (http://www.genome.jp/kegg/), using object search in
KEGG pathways. Random gene lists were used as reference.
Supporting Information
Figure S1 Western blot of Dysferlin IP. Dysferlin was immuno-
precipitated from IM2 myoblasts, IM2 myotubes and human
skeletal muscle tissue. Input, non-bound (NB) second wash, and
bound (B) fractions were analyzed on western blot for Dysferlin
and Tubulin content. Arrows denote the protein bands. As
expected Dysferlin is detected in all input and non-bound
fractions. In addition it is also identified in the bound fractions
for F4 and H7, but not the negative control IP 3A. Tubulin has a
similar pattern.
Found at: doi:10.1371/journal.pone.0013854.s001 (0.57 MB TIF)
Figure S2 Western blot for reported dysferlin interaction
partners. Dysferlin IP samples were probed on western blot for
Dysferlin, AHNAK, and Calpain 3. AHNAK and Calpain 3
specifically co-immunoprecipitate with Dysferlin. Arrows denote
the protein bands.
Found at: doi:10.1371/journal.pone.0013854.s002 (0.57 MB TIF)
Figure S3 Concept profiling and co-expression analysis. The
area under the ROC curve (AuC) was calculated for concept
profiles, and is plotted for all thee datasets. The AuC is 0.76 for
Proliferation, 0.78 for Differentiation, 0.77 for Tissue. B) The AuC
was calculated for GeneAtlas, and is plotted for all thee datasets.
The AuC is 0.72 for Proliferation, 0.73 for Differentation, 0.73 for
Tissue.
Found at: doi:10.1371/journal.pone.0013854.s003 (0.11 MB TIF)
Table S1 Proteins identified in the dysferlin protein complex.
For each protein the IPI reference, Official Gene Symbol, and
EntrezGene Identifier are shown.
Found at: doi:10.1371/journal.pone.0013854.s004 (0.11 MB
XLS)
Table S2 List of proteins identified by mass spectrometry. The
number of total and unique peptides is limited to peptides with an
individual Mascot score above 30 and the protein coverage is
based on these peptides only. The tables are ranked based on
emPAI scores [64].
Found at: doi:10.1371/journal.pone.0013854.s005 (0.20 MB
XLS)
Table S3 Conceptual analysis of the dysferlin protein complex.
Identified proteins were clustered in the webtool Anni, and the
clusters subsequently annotated with concepts. For each cluster the
associated proteins are shown, together with a representative
associated concept.
Found at: doi:10.1371/journal.pone.0013854.s006 (0.03 MB
XLS)
Table S4 DAVID analysis of the dysferlin protein complex.
Identified proteins were uploaded into DAVID and analyzed
against a background set of random proteins. Protein were
clustered based on GO terms, and strongest overrepresented
clusters are shown. In bold is the representative GO term that is
shown in Table 2.
Found at: doi:10.1371/journal.pone.0013854.s007 (1.09 MB
XLS)
Table S5 KEGG pathway representation. Pathways that relate
to calcium signaling and vesicle trafficking are in bold, the other
pathways indicate potential new roles of dysferlin. Of interest are
the immunoregulatory processes that relate to antigen processing,
phagocytosis and migration, as dysferlin is expressed in immune
cells. For each pathway the number of associated genes is given.
The disease-linked pathways Huntington, Parkinson and Alzhei-
mer disease, refer to metabolic, mitochondrial enzymes, and
reflect signaling pathways secondary to those diseases.
Found at: doi:10.1371/journal.pone.0013854.s008 (0.05 MB
DOC)
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